Development of vesicular acetylcholine transporter ligands: Molecular probes for alzheimer's disease

Current Bioactive Compounds

Volumn 6, Issue 3, 2010, Pages 129-155

  Giboureau, Nicolas ^a   Aumann, Kylee M ^a   Beinat, Corinne ^b   Kassiou, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alzheimer's disease; CNS; Denzovesamicol; Structure activity relationship; VAChT; Vesamicol

Indexed keywords

VESAMICOL; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; COGNITION; DRUG BINDING; DRUG MECHANISM; HUMAN; MEMORY; MOLECULAR PROBE; NEUROTRANSMISSION; PRIORITY JOURNAL; STEREOCHEMISTRY;

EID: 78650015548     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340710793237353     Document Type: Article

References (70)

1. Weihe, E.; Tao-Cheng, J.H.; Schafer, M.K.; Erickson, J.D.; Eiden, L.E. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles. Proc. Natl. Acad. Sci. USA, 1996, 93(8), 3547-3552.
2. Schafer, M.K.; Weihe, E.; Varoqui, H.; Eiden, L.E.; Erickson, J.D. Distribution of the vesicular acetylcholine transporter (VAChT) in the central and peripheral nervous systems of the rat. J. Mol. Neurosci: MN, 1994, 5(1), 1-26.
3. Roghani, A.; Feldman, J.; Kohan, S.A.; Shirzadi, A.; Gundersen, C.B.; Brecha, N.; Edwards, R.H. Molecular cloning of a putative vesicular transporter for acetylcholine. Proc. Natl. Acad. Sci. USA, 1994, 91(22), 10620-10624.
4. Ichikawa, T.; Ajiki, K.; Matsuura, J.; Misawa, H. Localization of two cholinergic markers, choline acetyltransferase and vesicular acetylcholine transporter in the central nervous system of the rat: in situ hybridization histochemistry and immunohistochemistry. J. Chem. Neuroanat., 1997, 13(1), 23-39.
5. Gilmor, M.L.; Nash, N.R.; Roghani, A.; Edwards, R.H.; Yi, H.; Hersch, S.M.; Levey, A.I. Expression of the putative vesicular acetylcholine transporter in rat brain and localization in cholinergic synaptic vesicles. J. Neurosci., 1996, 16(7), 2179-2190.
6. Erickson, J.D.; Varoqui, H.; Schafer, M.K.; Modi, W.; Diebler, M.F.; Weihe, E.; Rand, J.; Eiden, L.E.; Bonner, T.I.; Usdin, T.B. Functional identification of a vesicular acetylcholine transporter and its expression from a cholinergic gene locus. J. Biol. Chem., 1994, 269(35), 21929-21932.
7. Bejanin, S.; Cervini, R.; Mallet, J.; Berrard, S. A unique gene organization for two cholinergic markers, choline acetyltransferase and a putative vesicular transporter of acetylcholine. J. Biol. Chem., 1994, 269(35), 21944-21947.
8. de Castro, B.M.; De Jaeger, X.; Martins-Silva, C.; Lima, R.D.F.; Amaral, E.; Menezes, C.; Lima, P.; Neves, C.M.L.; Pires, R.G.; Gould, T.W.; Welch, I.; Kushmerick, C.; Guatimosim, C.; Izquierdo, I.; Cammarota, M.; Rylett, R.J.; Gomez, M.V.; Caron, M.G.; Oppenheim, R.W.; Prado, M.A.M.; Prado, V.F. The vesicular acetylcholine transporter is required for neuromuscular development and function. Mol. Cell Biol., 2009, 29(19), 5238-5250.
9. Guidine, P.A.M.; Rezende, G.H.S.; Queiroz, C.M.T.; Mello, L.E.; Prado, V.F.; Prado, M.A.M.; Pereira, G.S.; Moraes, M.F.D. Vesicular acetylcholine transporter knockdown mice are more susceptible to pilocarpine induced status epilepticus. Neurosci. Lett., 2008, 436(2), 201-204.
10. Lara, A.; Damasceno, D.D.; Pires, R.; Gros, R.; Gomes, E.R.; Gavioli, M.; Lima, R.F.; Guimaraes, D.; Lima, P.; Bueno, C.R., Jr.; Vasconcelos, A.; Roman-Campos, D.; Menezes, C.A.S.; Sirvente, R.A.; Salemi, V.M.; Mady, C.; Caron, M.G.; Ferreira, A.J.; Brum, P.C.; Resende, R.R.; Cruz, J.S.; Gomez, M.V.; Prado, V.F.; de Almeida, A.P.; Prado, M.A.M.; Guatimosim, S. Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol. Cell Biol., 2010, 30(7), 1746-1756.
11. Lima, R.D.F.; Prado, V.F.; Prado, M.A.M.; Kushmerick, C. Quantal release of acetylcholine in mice with reduced levels of the vesicular acetylcholine transporter. J. Neurochem., 2010, 113(4), 943-951.
12. Sato, T.; Abe, T.; Chida, D.; Nakamoto, N.; Hori, N.; Kokabu, S.; Sakata, Y.; Tomaru, Y.; Iwata, T.; Usui, M.; Aiko, K.; Yoda, T. Functional role of acetylcholine and the expression of cholinergic receptors and components in osteoblasts. FEBS Lett., 2010, 584(4), 817-824.
13. Masson, J.; Sagne, C.; Hamon, M.; El Mestikawy, S. Neurotransmitter transporters in the central nervous system. Pharmacol. Rev., 1999, 51(3), 439-464.
14. Evans, D.A.; Funkenstein, H.H.; Albert, M.S.; Scherr, P.A.; Cook, N.R.; Chown, M.J.; Hebert, L.E.; Hennekens, C.H.; Taylor, J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA, 1989, 262(18), 2551-2556.
15. Katzman, R., Early detection of senile dementia. Hosp. Pract. (Off Ed), 1981, 16(6), 61-76.
16. Coyle, J.T.; Price, D.L.; DeLong, M.R. Alzheimer's disease: a disorder of cortical holinergic innervation. Science, 1983, 219(4589), 1184-1190.
17. Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215(4537), 1237-1239.
18. Whitehouse, P.J.; Price, D.L.; Clark, A.W.; Coyle, J.T.; DeLong, M.R., Alzheimer disease: evidence for selectiveloss of cholinergic neurons in the nucleus basalis. Ann. Neurol., 1981, 10(2), 122-126.
19. Francis, P.T.; Palmer, A.M.; Snape, M.; Wilcock, G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol. Neurosurg. Psychiatry, 1999, 66(2), 137-147.
20. Rylett, R.J.; Ball, M.J.; Colhoun, E.H. Evidence for high affinity choline transport in synaptosomes prepared from hippocampus and neocortex of patients with Alzheimer's disease. Brain Res., 1983, 289(1-2), 169-175.
21. Perry, R.H.; Blessed, G.; Perry, E.K.; Tomlinson, B.E. Histochemical observations on cholinesterase activities in the brains of elderly normal and demented (Alzheimer-type) patients. Age Ageing, 1980, 9(1), 9-16.
22. Perry, E.K., The cholinergic system in old age and Alzheimer's disease. Age Ageing, 1980, 9(1), 1-8.
23. Perry, E.K.; Tomlinson, B.E.; Blessed, G.; Bergmann, K.; Gibson, P.H.; Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J., 1978, 2(6150), 1457-1459.
24. Mountjoy, C.Q.; Rossor, M.N.; Iversen, L.L.; Roth, M. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain, 1984, 107(Pt 2), 507-518.
25. Mountjoy, C.Q. Correlations between neuropathological and neurochemical changes. Br. Med. Bull., 1986, 42(1), 81-85.
26. Lazareno, S.; Popham, A.; Birdsall Nigel, J.M. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors. J. Mol. Neurosci: MN, 2002, 19(1-2), 123-127.
27. Watanabe, T.; Yamagata, N.; Takasaki, K.; Sano, K.; Hayakawa, K.; Katsurabayashi, S.; Egashira, N.; Mishima, K.; Iwasaki, K.; Fujiwara, M. Decreased acetylcholine release is correlated to memory impairment in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res., 2009, 1249, 222-228.
28. Cortes, F.; Portet, F.; Touchon, J.; Vellas, B. Six and 18- month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? J. Nutr. Health Aging, 2007, 11(4), 330-337.
29. Oddo, S.; LaFerla, F.M. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J. Physiol. (Paris), 2006, 99(2-3), 172-179.
30. Usdin, T.B.; Eiden, L.E.; Bonner, T.I.; Erickson, J.D. Molecular biology of the vesicular ACh transporter. Trends Neurosci., 1995, 18(5), 218-224.
31. Gilmor, M.L.; Counts, S.E.; Wiley, R.G.; Levey, A.I. Coordinate expression of the vesicular acetylcholine transporter and choline acetyltransferase following septohippocampal pathway lesions. J. Neurochem., 1998, 71(6), 2411-2420.
32. Efange, S.M. In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter. FASEB J., 2000, 14(15), 2401-2413.
33. Marshall, I.G. Studies on the blocking action of 2-(4-phenyl piperidino) cyclohexanol (AH5183). Br. J. Pharmacol., 1970, 38(3), 503-516.
34. Brittain, R.T.; Levy, G.P.; Tyers, M.B. The neuromuscular blocking action of 2-(4-phenylpiperidino)cyclohexanol (AH 5183). Eur. J. Pharmacol., 1969, 8(1), 93-99.
35. Efange, S.M.; Khare, A.B.; Langason, R.B. Comparative tissue distribution of conformationally restricted radioio dinated vesamicol receptor ligands. Nucl. Med. Biol., 1995, 22(4), 437-444.
36. Wolfe, S.A., Jr.; Culp, S.G.; De Souza, E.B. Sigmareceptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology, 1989, 124(3), 1160-1172.
37. 11C]SA6298 as a PET σ1 receptor ligand. Nucl. Med. Biol., 1999, 26(8), 915-922.
38. 11C]SA4503 as a PET ligand for mapping CNS σ1 receptors. Nucl. Med. Biol., 2000, 27(3), 255-261.
39. 3H]-3- (3-hydroxyphenyl)-N-(1-propyl)piperidine. J. Neurosci., 1986, 6(6), 1757-1770.
40. Graybiel, A.M.; Besson, M.J.; Weber, E. Neurolepticsensitive binding sites in the nigrostriatal system: evidence for differential distribution of sigma sites in the substantia nigra, pars compacta of the cat. J. Neurosci., 1989, 9(1), 326-338.
41. 3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative σ1 and σ2 receptor subtypes. Neuroscience, 1997, 76(2), 467-477.
42. Aanonsen, L.M.; Seybold, V.S. Phencyclidine and sigma receptors in rat spinal cord: binding characterization and quantitative autoradiography. Synapse, 1989, 4(1), 1-10.
43. Walker, J.M.; Bowen, W.D.; Walker, F.O.; Matsumoto, R.R.; De Costa, B.; Rice, K.C. Sigma receptors: biology and function. Pharmacol. Rev., 1990, 42(4), 355-402.
44. Rogers, G.A.; Parsons, S.M.; Anderson, D.C.; Nilsson, L.M.; Bahr, B.A.; Kornreich, W.D.; Kaufman, R.; Jacobs, R.S.; Kirtman, B. Synthesis, in vitro acetylcholine-storageblocking activities, and biological properties of derivatives and analogues of trans-2-(4-phenylpiperidino)cyclohexanol (vesamicol). J. Med. Chem., 1989, 32(6), 1217-1230.
45. Shiba, K.; Mori, H.; Ichikawa, A.; Tonami, N. In vitro characterization of radioiodinated (-)-m-iodovesamicol in rat cerebral membranes. Life Sci, 1996, 59(13), 1039-1045.
46. Shiba, K.; Mori, H.; Ikeda, E.; Sumiya, H.; Tonami, N. The potential of radioiodinated (-)-m-iodovesamicol for diagnosing cholinergic deficit dementia. Nucl. Med. Biol., 2001, 28(3), 261-264.
47. Shiba, K.; Mori, H.; Matsuda, H.; Ichikawa, A.; Tonami, N. Radioiodinated (-)-2-[4-(3-iodophenyl) piperidino] cyclohexanol: a potential radioligand for mapping presynaptic cholinergic neurons. Nucl. Med. Commun., 1996, 17(6), 485-492.
48. Shiba, K.; Mori, H.; Matsuda, H.; Tsuji, S.; Kuji, I.; Sumiya, H.; Kinuya, K.; Tonami, N.; Hisada, K.; Sumiyosi, T. Synthesis of radioiodinated analogs of 2-(4-phenylpiperidino) cyclohexanol (vesamicol) as vesamicol-like agent. Nucl. Med. Biol., 1995, 22(2), 205-210.
49. Shiba, K.; Mori, H.; Matsuda, H.; Tsuji, S.; Tonami, N.; Hisada, K. In vivo characterization of radioiodinated 2-(4-phenylpiperidino)cyclohexanol (vesamicol) analogs: potential radioligand for mapping presynaptic cholinergic neurons. Nucl. Med. Biol., 1995, 22(6), 823-828.
50. Shiba, K.; Ogawa, K.; Ishiwata, K.; Yajima, K.; Mori, H. Synthesis and binding affinities of methylvesamicol analogs for the acetylcholine transporter and sigma receptor. Bioorg. Med. Chem., 2006, 14(8), 2620-2626.
51. Shiba, K.; Ogawa, K.; Mori, H. In vitro characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino] cyclohexanol [(+)-pIV] as a sigma-1 receptor ligand. Bioorg. Med. Chem., 2005, 13(4), 1095-1099.
52. Shiba, K.; Yano, T.; Sato, W.; Mori, H.; Tonami, N. Characterization of radioiodinated (-)-ortho-iodovesamicol binding in rat brain preparations. Life Sci., 2002, 71(13), 1591-1598.
53. Efange, S.M.; Khare, A.B.; Foulon, C.; Akella, S.K.; Parsons, S.M. Spirovesamicols: conformationally restricted analogs of 2-(4-phenylpiperidino)cyclohexanol (vesamicol, AH5183) as potential modulators of presynaptic cholinergic function. J. Med. Chem., 1994, 37(16), 2574-2582.
54. Efange, S.M.; Mach, R.H.; Smith, C.R.; Khare, A.B.; Foulon, C.; Akella, S.K.; Childers, S.R.; Parsons, S.M. Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem. Pharmacol., 1995, 49(6), 791-797.
55. Scheunemann, M.; Sorger, D.; Wenzel, B.; Heinitz, K.; Schliebs, R.; Klingner, M.; Sabri, O.; Steinbach, J. Synthesis of novel 4- and 5-substituted benzyl ether derivatives of vesamicol and in vitro evaluation of their binding properties to the vesicular acetylcholine transporter site. Bioorg. Med. Chem., 2004, 12(6), 1459-1465.
56. Jung, Y.W.; Frey, K.A.; Mulholland, G.K.; del Rosario, R.; Sherman, P.S.; Raffel, D.M.; Van Dort, M.E.; Kuhl, D.E.; Gildersleeve, D.L.; Wieland, D.M. Vesamicol receptor mapping of brain cholinergic neurons with radioiodinelabeled positional isomers of benzovesamicol. J. Med. Chem., 1996, 39(17), 3331-3342.
57. Efange, S.M.; Khare, A.B.; Mach, R.H.; Parsons, S.M. Hydroxylated decahydroquinolines as ligands for the vesicular acetylcholine transporter: synthesis and biological evaluation. J. Med. Chem., 1999, 42(15), 2862-2869.
58. 18Flabeled fluoroacetylmorpholino derivative of vesamicol for neuroimaging of the vesicular acetylcholine transporter. Nucl. Med. Biol., 2008, 35(2), 185-195
59. 18F]fluoro-benzoyl derivative of 7-hydroxy-6-(4- phenyl-piperidin-1-yl)-octahydro-benzo[1,4]oxazines. Nucl. Med. Biol., 2009, 36(1), 17-27.
60. 18F-labeled Positron Emission Tomography (PET) ligands for imaging the vesicular acetylcholine transporter. J. Med. Chem., 2009, 52(5), 1358-1369.
61. Efange, S.M.; Boudreau, R.J. Molecular determinants in the bioactivation of the dopaminergic neurotoxin N-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP). J. Comput. Aided Mol. Des., 1991, 5(5), 405-417.
62. Zea-Ponce, Y.; Mavel, S.; Assaad, T.; Kruse, S.E.; Parsons, S.M.; Emond, P.; Chalon, S.; Giboureau, N.; Kassiou, M.; Guilloteau, D. Synthesis and in vitro evaluation of new benzovesamicol analogs as potential imaging probes for the vesicular acetylcholine transporter. Bioorg. Med. Chem., 2005, 13(3), 745-753.
63. Bando, K.; Taguchi, K.; Ginoza, Y.; Naganuma, T.; Tanaka, Y.; Koike, K.; Takatoku, K. Synthesis and evaluation of radiolabeled piperazine derivatives of vesamicol as SPECT agents for cholinergic neurons. Nucl. Med. Biol.,2001, 28(3), 251-260.
64. Bando, K.; Naganuma, T.; Taguchi, K.; Ginoza, Y.; Tanaka, Y.; Koike, K.; Takatoku, K. Piperazine analog of vesamicol: in vitro and in vivo characterization for vesicular acetylcholine transporter. Synapse, 2000, 38(1), 27-37.
65. 125I]MIBT in primate brain. Eur. J. Pharmacol., 1997, 338(2), 159-169.
66. 18F]spiro-FBT]: synthesis and biological evaluation of a high-affinity ligand for the vesicular acetylcholine transporter (VAChT). Nucl. Med. Biol., 1999, 26(2), 189-192.
67. 125I]MIBT): potential radioligand for mapping central cholinergic innervation. J. Med. Chem., 1993, 36(12), 1754-1760.
68. 125I]-MIBT] reveals blunting of the striatal cholinergic response to dopamine D2 receptor blockade in the 6-hydroxydopamine (6-OHDA)-lesioned rat: possible implications for Parkinson's disease. Life Sci., 1996, 58(16), 1367-1374.
69. Efange, S.M.; Khare, A.; Parsons, S.M.; Bau, R.; Metzenthin, T. Nonsymmetrical bipiperidyls as inhibitors of vesicular acetylcholine storage. J. Med. Chem., 1993, 36(8), 985-989.
70. Efange, S.M.; Michelson, R.H.; Dutta, A.K.; Parsons, S.M., Acyclic analogues of 2-(4-phenylpiperidino)cyclohexanol (vesamicol): conformationally mobile inhibitors of vesicular acetylcholine transport. J. Med. Chem., 1991, 34(8), 2638-2643.